Financial Conflict of Interest Policy

Policy Number SR 12-01

Effective date: August 24, 2012

Designated Institute Official (DIO): Eion Ramcharan

PURPOSE
The purpose of this Policy is to ensure compliance of the Max Planck Florida Institute for Neuroscience (Institute) with Federal Regulations (42 CFR Part 50, Subpart F for PHS grants and cooperative agreements) which outlines the responsibilities of applicants for promoting objectivity in Public Health Service (PHS) funded research. The Policy aims to establish standards so that there is no reasonable expectation that the design, conduct, or reporting of research funded under NIH grants or cooperative agreements will be biased by any conflicting financial interest of an Investigator. This regulation is commonly referred to as the Financial Conflict of Interest (FCOI) regulation.

APPLICABILITY
The policy applies to Investigators participating in PHS research, as defined by PHS regulations including sub-grantee/contractor/collaborating Investigators, but excluding applications for Phase I support under the SBIR and Small Business Technology Transfer (STTR) programs.

DEFINITIONS
1. **HHS.** The United States Department of Health and Human Services, and any components of the Department to which the authority involved may be delegated.

2. **Institution (Institute).** Any domestic or foreign, public or private, entity or organization (excluding a Federal agency).

3. **Investigator.** The principal investigator and any other person, who is responsible for the design, conduct, or reporting of research funded by PHS, or proposed for such funding. For purposes of the requirements of this subpart relating to financial interests, “Investigator” includes the Investigator’s spouse and dependent children.

4. **PHS** means the Public Health Service, an operating division of the U.S. Department of Health and Human Services, and any components of the PHS to which the authority involved may be delegated.

5. **PHS Awarding Component.** The organizational unit of the PHS that funds the research.

6. **Research.** A systematic investigation designed to develop or contribute to overall knowledge relating broadly to public health, including behavioural and social sciences research. The term encompasses basic and applied research and product
development. The term includes any such activity for which research funding is available from a PHS Awarding Component through a grant or cooperative agreement, whether authorized under the PHS Act or other statutory authority.

7. **Significant Financial Interest.** Anything of monetary value, including but not limited to, salary or other payments for services (e.g., consulting fees or honoraria); equity interests (e.g., stocks, stock options or other ownership interests); intellectual property rights (e.g., patents, copyrights and royalties from such rights); and travel paid on behalf of the investigator and not reimbursed to the investigator related to institutional responsibilities unless reimbursed or sponsored by excluded sources (by a federal, state or local government agency or an institution of higher education). The term does not include:
   a. Salary, royalties, or other remuneration from the **Institute**.
   b. Any ownership interests in the **Institute**, if the **Institute** is an applicant under the SBIR Program.
   c. Income from seminars, lectures, or teaching engagements sponsored by public or nonprofit entities.
   d. Income from service on advisory committees or review panels for public or nonprofit entities.
   e. An equity interest that when aggregated for the Investigator and the Investigator's spouse and dependent children, meets both of the following tests: Does not exceed $5,000 in value as determined through reference to public prices or other reasonable measures of fair market value, and does not represent more than a five percent ownership interest in any single entity; or salary, royalties or other payments that when aggregated for the Investigator and the Investigator's spouse and dependent children over the next twelve months, are not expected to exceed $5,000.

8. **Small Business Innovation Research (SBIR) Program.** The extramural research program for small business that is established by the Awarding Components of the Public Health Service and certain other Federal agencies under Pub. L. 97–219, the Small Business Innovation Development Act, as amended. For purposes of this subpart, the term SBIR Program includes the Small Business Technology Transfer (STTR) Program, which was established by Pub. L. 102–564

**POLICY STATEMENT**
No employee of the **Institute** should have any interest, financial or otherwise, direct or indirect, or engage in any business or transaction or professional activity or incur any obligation of any nature that is in substantial conflict with the proper discharge of their duties in the best interests of the **Institute**.

No investigator of the **Institute** should have any financial interest that will, or may be reasonably expected to, bias the design, conduct, or reporting of sponsored programs. All investigators must have a current Disclosure Statement on file with the **Institute**.

**DISCLOSURE STATEMENT**
The Disclosure Statement that is made a part of this conflict of interest policy as **Attachment I** must be completed by investigators who are applying for funds from an
external sponsor or those who have not filed a disclosure statement in conformance with Institute’s conflict of interest policy. Disclosure statements must be filed at the time of application and updated either annually or as new reportable significant financial interests are obtained.

**REAL, APPARENT, OR POTENTIAL CONFLICTS**
All real, apparent, or potential conflicts of interest as defined under the Policy Statement must be disclosed for review and determination as to whether a violation of this policy exists.

**COMPLAINTS AND INQUIRIES**
Anyone may bring a complaint or make inquiries concerning possible violation of this conflict of interest policy. All complaints or inquiries should be immediately reported to the DIO or designee. Upon receipt or notification of such complaint or inquiry, the DIO or designee shall immediately advise the CEO and the person against whom the complaint is made.

**INVESTIGATOR TRAINING**
Each investigator must complete FCOI training:
1. Prior to engaging in research related to PHS funded research received after August 24, 2012;
2. At least every four years;
3. If the Institute revises FCOI policy;
4. When an investigator is new to the Institute;
5. When an investigator is found to be noncompliant with the Institute’s FCOI policy
To complete training:
2. View tutorial and answer the review questions
3. At the end of the tutorial, click the “Certificate” button
4. When the certificate appears, type your name in the Participant’s Name text box
5. Print, and turn into DIO

**PROCEDURES FOR INVESTIGATING FCOI**
The DIO will review all financial disclosures. Affected individual(s) will be afforded confidential treatment to the maximum extent possible, and are entitled to a prompt and thorough investigation and an opportunity to comment on any allegations or findings resulting from the investigation. The DIO, or designee, shall advise the Director and CEO of the Institute of the substance of the disclosure. The CEO shall appoint an independent panel to determine whether a conflict of interest exists and, if so, determine what actions should be taken by the Institute to manage, reduce or eliminate such conflict of interest. A conflict of interest exists when the designated panel reasonably determines that a Significant Financial Interest could directly and significantly affect the design, conduct, or reporting of the PHS-funded research or
the Investigator’s institutional responsibilities. Examples of conditions or restrictions that might be imposed to manage conflicts of interest include, but are not limited to:

1. Public disclosure of significant financial interests.
2. Monitoring of research by independent reviewers.
3. Modification of the research plan.
4. Disqualification from participation in all or a portion of the research funded by the PHS.
5. Divestiture of significant financial interests.
6. Severance of relationships that create actual or potential conflicts.

In addition to the types of conflicting financial interests described in this paragraph that must be managed, reduced, or eliminated, the Institute may require the management of other conflicting financial interests, as it deems appropriate.

**PHS NOTIFICATION**

If the failure of an Investigator to comply with the conflict of interest policy of the Institute has prejudiced the design, conduct, or reporting of the PHS-funded research, the Institute will promptly notify the PHS Awarding Component of the action it has taken or intends to take. The PHS Awarding Component will consider the situation and, as necessary, take appropriate action, or refer the matter to the Institute for further action. These may include directing the Institute on how to maintain appropriate objectivity in the funded project.

The HHS may at any time inquire into the Institute procedures and actions regarding conflicting financial interests in PHS-funded research, including a requirement for submission of, or review on site, all records pertinent to compliance. To the extent permitted by law, HHS will maintain the confidentiality of all records of financial interests. On the basis of its review of records and/or other information that may be available, the PHS Awarding Component may decide that a particular conflict of interest will bias the objectivity of the PHS-funded research to such an extent that further corrective action is needed or that the Institute has not managed, reduced, or eliminated the conflict of interest. The PHS Awarding Component may determine that suspension of funding under 45 CFR 74.62 is necessary until the matter is resolved.

**RETENTION OF DOCUMENTATION**

Detailed documentation of each review will be maintained for at least three (3) years, and will, upon request, be provided to the official(s) of the Institute. Documentation to substantiate an investigation’s findings will be retained for at least three (3) years after completion of a final report.

**APPEAL**

An investigator or employee who disagrees with the determination of the review panel may appeal to the CEO of the Institute, or the CEO’s designee, for reconsideration of such determination. The determination of the CEO shall be final and binding.
Disclosure of Financial Conflict of Interest Status

Federal regulations require that the Max Planck Florida Institute (Institute), reduce, or eliminate any actual or potential conflicts of interest that may be presented by the compensated outside activities and other financial interests of persons involved in sponsored research projects. In keeping with Federal Regulations (42 CFR Part 50, Subpart F), the Max Planck Florida Institute requires that this form be submitted with every proposal for sponsored research or educational activities and be updated periodically.

Type of Disclosure: (check one) ☐ Proposal Submission ☐ Annual Update ☐ Periodic Revision

*Investigator: ____________________________ Department: ________________
Title of Proposal/Project: ____________________________
Principal Investigator (if different): ____________________________
☐ I have no significant financial interest(s)* that would reasonably appear to affect or be affected by this proposed or funded sponsored project.

☐ I am disclosing the following significant financial interest(s)* that would reasonably appear to affect or be affected by this proposed sponsored project, and I am attaching supporting documentation that identifies the business enterprise or entity involved and the nature and amount of the interest:

☐ Salary or other payments for services such as consulting fees and honoraria.
☐ Equity interests, such as stocks and stock options.
☐ Intellectual property rights, such as patents, copyrights, and royalties.
☐ Travel paid on my behalf
☐ Other significant financial interests that possibly would affect or be perceived to affect the results of the research, educational or service activities funded or proposed for funding.

☐ Further, I agree:
• to update this disclosure annually during the period of the award and any time new reportable significant financial interests are obtained,
• and to comply with any conditions or restrictions imposed by the Max Planck Florida Institute to manage, reduce or eliminate actual or potential conflicts of interest, or forfeit the award.

Investigator's signature: ____________________________ Date: ________________
(Original signatures only; a "per" signature is unacceptable)
This form must accompany all proposals.

* Definitions:
For the purpose of this disclosure, investigator is defined as the Principal Investigator/Project Director, Co-Principal Investigator, and any other persons who is responsible for the design, conduct, or reporting of research, educational or service activities funded (or proposed for funding) by an external sponsor.

For the purpose of this disclosure, significant financial interest(s) are defined as salary or other payment for services or intellectual property rights that, when aggregated over the next twelve months for an investigator or his/her spouse and dependent children, are expected to exceed $5,000; and equity or ownership interests held by an investigator, or his/her spouse and dependent children, that represents more than a five percent ownership interest or exceeds $5,000 in value.